How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 73.4 | 73.4 | 71.8 | 69.0 | 69.0 | 69.0 | -4.4 |
| Healthcare | 24.8 | 24.8 | 26.8 | 29.3 | 29.3 | 29.3 | +4.5 |
| Chemicals | 1.0 | 1.0 | 0.8 | 1.1 | 1.1 | 1.1 | +0.1 |
| Unclassified | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.0 |
| Digital | 0.5 | 0.5 | 0.5 | · | · | · | +0.0 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 11.13% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| DIVISLAB | Pharma | 8.03% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| JBCHEPHARM | Pharma | 6.45% | 9 | 7 | 2 | 5 | 1 | 1/2 | +18.6% |
| GLENMARK | Pharma | 6.40% | 6 | 9 | 10 | 4 | 3 | 0/2 | +1.5% |
| APOLLOHOSP | Healthcare | 6.04% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| LAURUSLABS | Pharma | 4.35% | 8 | 9 | 4 | 4 | 1 | 0/2 | +34.0% |
| LUPIN | Pharma | 4.28% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| DRREDDY | Pharma | 4.27% | 7 | 2 | 5 | 1 | 7 | 0/2 | -0.3% |
| AUROPHARMA | Pharma | 4.12% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| FORTIS | Healthcare | 3.88% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| ALKEM | Pharma | 3.57% | 9 | 8 | 8 | 10 | 6 | 1/2 | +0.5% |
| KIMS | Healthcare | 3.55% | 7 | 3 | 7 | 4 | 1 | 0/2 | +19.2% |
| ONESOURCE | Healthcare | 3.26% | 3 | 1 | 5 | 7 | 8 | 0/2 | +9.7% |
| ERIS | Pharma | 3.25% | 5 | 7 | 5 | 6 | 6 | 0/2 | +1.0% |
| SAILIFE | Healthcare | 3.23% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| CIPLA | Pharma | 3.21% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| ASTERDM | Healthcare | 3.10% | 10 | 4 | 8 | 3 | 1 | 1/2 | +15.1% |
| IPCALAB | Pharma | 3.02% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| LALPATHLAB | Healthcare | 2.54% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
| MAXHEALTH | Healthcare | 2.35% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| GLAND | Pharma | 2.23% | 9 | 8 | 6 | 6 | 4 | 0/2 | +38.5% |
| MANKIND | Pharma | 2.07% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
| NH | Healthcare | 1.33% | 9 | 8 | 8 | 2 | 3 | 0/2 | +10.3% |
| ANTHEM | Pharma | 1.20% | 7 | 10 | 3 | 5 | 2 | 0/2 | -2.3% |
| BIOCON | Pharma | 0.56% | 6 | 1 | 10 | 5 | 3 | 0/2 | +12.5% |
| DEEPAKNTR | Chemicals | 0.50% | 3 | 2 | 1 | 3 | 5 | 0/2 | +7.6% |
| TORNTPHARM | Pharma | 0.46% | 10 | 8 | 5 | 6 | 1 | 1/2 | +14.6% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹194 (+94%), vs ₹169 for Nifty 500 (+69%) and ₹152 for Nifty 50 (+52%). Its relative-strength line ended at 128 vs Nifty 50 and 115 vs Nifty 500 — above 100, sustained outperformance.